Now, according to a new study published in the early online edition of Proceedings of the National Academy of Sciences of the USA (PNAS), scientists from the Université de Montréal and the Maisonneuve-Rosemont Hospital Research Centre have identified a new biochemical pathway which controls DNA repair.

"Our study is the first to identify a regulatory role for the ATR protein in a specific DNA repair system, which is called nucleotide excision repair or NER," says Elliot Drobetsky, senior author and associate professor of immunology and oncology at the Université de Montréal.

"NER is a critical DNA repair system that removes pieces of damaged DNA before these pieces can be converted into genetic mutations that destroy the function of tumour-preventing proteins in the body. Characterizing how the NER system is turned on or off is critical to understanding how tumours develop. In this system, ATR is the key that turns on the repair machinery."

ATR-mediated NER often defective in tumour cells

The scientific team used cultured lung cells to investigate the role of ATR in NER function. They found that inhibiting ATR resulted in a dysfunctional NER system and, during a very critical period of the cell's growth cycle, damaged DNA was not repaired at all.

What's more, they discovered that some tumour cell lines are completely deficient in ATR-mediated NER, which provides solid evidence that the DNA repair function of ATR may be pivotal in cancer development. "Our study reveals an original mechanism to explain how exposure to environmental carcinogens initiate and promote cancer," adds Dr. Drobetsky.

Chemotherapy implications

The goal of conventional chemotherapy is to kill tumour cells – leaving normal cells relatively unaffected – by damaging their DNA. As such, in what may seem paradoxical, many chemotherapeutic drugs which are used to cure cancer are themselves powerful carcinogens that can also cause cancer.

"As shown in the current study, a non-functional ATR pathway resulting in limited DNA repair may be characteristic of many tumour cell types, but not of normal noncancerous cells. Determining if the NER system is working in patient tumours may therefore be an important first step to chemotherapy prescribing practices," says Yannick Auclair, the study's lead author and a PhD student at the Université de Montréal.

Any tumours identified as defective in ATR-mediated repair are expected to respond extremely well to chemotherapy, because the cells in these tumours would be extremely hypersensitive to certain anti-cancer drugs unlike normal cells in the rest of the body.

"These findings open a whole new area of research," says Dr. Drobetsky. "Our data harbour critical implications not only for understanding how cancer develops but also for devising new strategies to greatly improve cancer treatment."

About the study: The article "ATR kinase is required for global-genomic nucleotide excision repair exclusively during S phase in human cells," (http://www.pnas.org/content/current) published in Proceedings of the National Academy of Sciences of the USA (PNAS), was authored by Yannick Auclair, Raphael Rouget, El Bachir Affar and Elliot A. Drobetsky of the Université de Montréal and Maisonneuve-Rosemont Hospital Research Centre.

Partners in research: This study was funded through grants from the Canadian Institutes of Health Research.

Note: If no author is given, the source is cited instead.

• Genes
• Lung Cancer
• Cancer
• Ovarian Cancer
• Colon Cancer
• Breast Cancer

• DNA repair
• Tumor suppressor gene
• BRCA1
• Mutation
• BRCA2
• Tumor